We are live on
!
Find out more
IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
1-Year Est. Return
17.25%
This Fund
S&P 500
This Quarter
Est. Return
-4.35%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$222M
AUM Growth
–
Cap. Flow
+$226M
Cap. Flow
% of AUM
102.02%
Top 10 Holdings %
Top 10 Hldgs %
61.86%
Holding
49
New
49
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$20.2M |
| 2 |
Biogen
BIIB
|
+$19.5M |
| 3 |
SHPG
Shire pic
SHPG
|
+$16.9M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$16.4M |
| 5 |
Gilead Sciences
GILD
|
+$13.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $21M | 9.48% |
+181,722
| New | +$20.2M |
|
|
2
Biogen
BIIB
$32.7B
| $18.7M | 8.42% |
+65,908
| New | +$19.5M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
| $16.4M | 7.38% |
+133,841
| New | +$16.4M |
|
|
SHPG
4
DELISTED
Shire pic
SHPG
| $16.2M | 7.31% |
+95,200
| New | +$16.9M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $12.7M | 5.72% |
+94,500
| New | +$11.9M |
|
|
6
Gilead Sciences
GILD
$185B
| $12.6M | 5.67% |
+175,784
| New | +$13.1M |
|
7
Regeneron Pharmaceuticals
REGN
$83.1B
| $11.9M | 5.37% |
+32,430
| New | +$12.3M |
|
8
Amgen
AMGN
$236B
| $11.7M | 5.28% |
+80,104
| New | +$12.1M |
|
|
ARIA
9
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $8.18M | 3.69% |
+657,912
| New | +$7.92M |
|
10
Incyte
INCY
$25.9B
| $7.9M | 3.56% |
+78,775
| New | +$7.69M |
|
11
Vertex Pharmaceuticals
VRTX
$139B
| $7.78M | 3.5% |
+105,522
| New | +$8.59M |
|
|
ENTL
12
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $7.63M | 3.44% |
+403,320
| New | +$7.74M |
|
13
Illumina
ILMN
$34.3B
| $7.16M | 3.23% |
+57,507
| New | +$7.75M |
|
14
BioMarin Pharmaceuticals
BMRN
$12.6B
| $6.27M | 2.82% |
+75,666
| New | +$6.51M |
|
|
AERI
15
DELISTED
Aerie Pharmaceuticals
AERI
| $5.21M | 2.35% |
+138,000
| New | +$5.22M |
|
|
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.33M | 1.5% |
+75,000
| New | +$2.64M |
|
|
ICPT
17
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.21M | 1.45% |
+29,555
| New | +$3.52M |
|
|
ADMS
18
DELISTED
Adamas Pharmaceuticals
ADMS
| $3.13M | 1.41% |
+185,234
| New | +$2.86M |
|
19
Ligand Pharmaceuticals
LGND
$5.67B
| $3.05M | 1.37% |
+48,090
| New | +$3.03M |
|
20
Exelixis
EXEL
$13.7B
| $2.76M | 1.24% |
+185,000
| New | +$2.67M |
|
|
FOMX
21
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.2M | 0.99% |
+197,838
| New | +$1.86M |
|
|
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
| $2.19M | 0.98% |
+322,436
| New | +$2.38M |
|
23
Vanda Pharmaceuticals
VNDA
$330M
| $2.17M | 0.98% |
+135,817
| New | +$2.18M |
|
24
Prothena Corp
PRTA
$465M
| $2.07M | 0.93% |
+42,000
| New | +$2.32M |
|
25
Jazz Pharmaceuticals
JAZZ
$16.3B
| $1.98M | 0.89% |
+18,200
| New | +$2.03M |
|
Similar funds
DCMIC
DT
3LCM
TFA
SFG
AEPLI
CC
BC
International Biotechnology Trust's Q4 2016 Portfolio in Review
Q4 2016 is the first quarter with a 13F filing on record for International Biotechnology Trust, which disclosed 49 positions worth $222M. Its ten largest holdings account for 62% of the portfolio.
Its largest position is Celgene Corp: 181,722 shares worth $21M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- International Biotechnology Trust's largest Q4 2016 buy was Celgene Corp: 181,722 shares worth $21M.
- International Biotechnology Trust's ten largest holdings make up 62% of its $222M portfolio in Q4 2016.
- International Biotechnology Trust disclosed 49 positions in Q4 2016, its first 13F filing on record.
Based on International Biotechnology Trust's 13F filing for Q4 2016, filed 2 Mar 2018.